22. Future Oncol. 2018 Apr;14(9):849-859. doi: 10.2217/fon-2017-0384. Epub 2018 Mar12.Comparison of primary breast cancer and paired metastases: biomarkers discordanceinfluence on outcome and therapy.Ongaro E(1)(2), Gerratana L(1)(3), Cinausero M(1)(2), Pelizzari G(1)(3), Poletto E(1), Giangreco M(3)(4), Andreetta C(1), Pizzolitto S(5), Di Loreto C(3)(6),Minisini AM(1), Mansutti M(1), Russo S(1), Fasola G(1), Puglisi F(3)(7).Author information: (1)Department of Oncology, Azienda Sanitaria Universitaria Integrata S Mariadella Misericordia, Pz.le S Maria della Misericordia 15, 33100  Udine (UD),Italy.(2)Department of Medicine, University of Verona, Azienda OspedalieraUniversitaria Integrata Policlinico GB Rossi, Pz.le LA Scuro 10, 37134 Verona(VR), Italy.(3)Department of Medicine (DAME), University of Udine, Pz.le Kolbe 3, 33100 Udine(UD), Italy.(4)Institute of Hygiene & Clinical Epidemiology, Azienda Sanitaria Universitaria Integrata S Maria della Misericordia, Pz.le S Maria della Misericordia 15, 33100 Udine (UD), Italy.(5)Department of Pathology, Azienda Sanitaria Universitaria Integrata S Mariadella Misericordia, Pz.le S Maria della Misericordia 15, 33100 Udine (UD), Italy.(6)Institute of Pathology, Azienda Sanitaria Universitaria Integrata S Mariadella Misericordia, Pz.le S Maria della Misericordia 15, 33100 Udine (UD), Italy.(7)Department of Clinical Oncology, CRO Aviano National Cancer Institute, ViaFranco Gallini 2, 33081 Aviano (PN), Italy.AIM: Discordance between primary tumor and paired metastases biology has beenwidely detected in metastatic breast cancer. The aim of this study was toevaluate the prognostic impact of Ki67, estrogen receptor (ER), progesteronereceptor (PR) and HER2 discordance.METHODS: We retrospectively analyzed a cohort of 544 patients affected bymetastatic breast cancer. Variation in ER, PR, Ki67 and HER2 expression betweenprimary site and recurrence was tested through the McNemar test.RESULTS: A significant variation was observed in respect to ER, PR and Ki67status (12.65%, p = 0.0072; 49.71%, p < 0.0001; 35%, p < 0.0001, respectively).Among patients with ER or PR discordance, the driver of therapeutic decisions wasthe ER status. Moreover, we observed a therapy-related reduction of ER in taxanesor aromatase inhibitors-exposed patients (odds ratio: 3.59; 95% CI: 1.66-7.77;p = 0.001 and odds ratio: 2.07; 95% CI: 0.96-4.44; p = 0.06, respectively).CONCLUSION: Biopsy of metastatic lesions may influence the decision-makingprocess translating into better outcome.DOI: 10.2217/fon-2017-0384 PMID: 29527957 